193 related articles for article (PubMed ID: 16352333)
1. Comparison of uterine malignancies that develop during and following tamoxifen therapy.
Ferguson SE; Soslow RA; Amsterdam A; Barakat RR
Gynecol Oncol; 2006 May; 101(2):322-6. PubMed ID: 16352333
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers.
Hachisuga T; Saito T; Kigawa J; Ohwada M; Yamazawa K; Yasue A; Iwasaka T; Sugiyama T; Kita T; Nagai N
Gynecol Oncol; 2004 Oct; 95(1):139-44. PubMed ID: 15385123
[TBL] [Abstract][Full Text] [Related]
3. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE; Hollema H; van Boven HH; Bergman E; de Leeuw-Mantel G; Platteel I; Fles R; Nederlof PM; Mourits MJ; van Leeuwen FE;
Breast Cancer Res Treat; 2008 Nov; 112(1):99-108. PubMed ID: 18064567
[TBL] [Abstract][Full Text] [Related]
5. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
[TBL] [Abstract][Full Text] [Related]
6. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
Slomovitz BM; Sun CC; Ramirez PT; Bodurka DC; Diaz P; Lu KH
Obstet Gynecol; 2004 Aug; 104(2):255-60. PubMed ID: 15291996
[TBL] [Abstract][Full Text] [Related]
7. Association between uterine serous carcinoma and breast cancer.
Gehrig PA; Bae-Jump VL; Boggess JF; Groben PA; Fowler WC; Van Le L
Gynecol Oncol; 2004 Jul; 94(1):208-11. PubMed ID: 15262144
[TBL] [Abstract][Full Text] [Related]
8. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
9. Carcinosarcoma arising in uterine didelphys after tamoxifen therapy for breast cancer: a case report.
Suprasert P; Khunamornpong S
J Med Assoc Thai; 2010 May; 93(5):608-12. PubMed ID: 20524448
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features.
Barakat RR; Wong G; Curtin JP; Vlamis V; Hoskins WJ
Gynecol Oncol; 1994 Nov; 55(2):164-8. PubMed ID: 7959278
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
12. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
13. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.
Hubalek M; Ramoni A; Mueller-Holzner E; Marth C
Gynecol Oncol; 2004 Oct; 95(1):264-6. PubMed ID: 15385144
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen.
Saadat M; Truong PT; Kader HA; Speers CH; Berthelet E; McMurtrie E; Olivotto IA
Cancer; 2007 Jul; 110(1):31-7. PubMed ID: 17510927
[TBL] [Abstract][Full Text] [Related]
15. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer.
Rieck GC; Freites ON; Williams S
J Obstet Gynaecol; 2005 Jan; 25(1):39-41. PubMed ID: 16147692
[TBL] [Abstract][Full Text] [Related]
16. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
17. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center.
Abu-Rustum NR; Alektiar K; Iasonos A; Lev G; Sonoda Y; Aghajanian C; Chi DS; Barakat RR
Gynecol Oncol; 2006 Nov; 103(2):714-8. PubMed ID: 16740298
[TBL] [Abstract][Full Text] [Related]
18. Myxoid leiomyosarcoma of the uterus in a patient receiving tamoxifen therapy: a case report.
Botsis D; Koliopoulos C; Kondi-Pafitis A; Creatsas G
Int J Gynecol Pathol; 2006 Apr; 25(2):173-5. PubMed ID: 16633068
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.
Owusu C; Lash TL; Silliman RA
Breast J; 2007; 13(4):374-82. PubMed ID: 17593042
[TBL] [Abstract][Full Text] [Related]
20. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]